The Food and Drug Administration (FDA) recently approved a first-of-its-kind medication for treating Parkinson’s disease. Patients take JUVMO daily, a prescription medication that mimics the ...

Juvmo was designed to offer a reduction in motor symptoms, while reducing non-motor side effects, through its more selective ...

AbbVie has won U.S. Food and Drug Administration approval of its Juvmo once-daily oral treatment for the progressive neurological disorder Parkinson's disease. AbbVie on Monday said the green light ...

JUVMO™ is the first and only selective D1/D5 receptor agonist approved for adults with Parkinson's disease1 Taken once daily with or without levodopa therapy, JUVMO offers patients ...

Tavapadon (Juvmo) is the first selective D1/D5 dopamine receptor agonist approved for adult Parkinson disease, positioning a mechanistically differentiated oral, once-daily dopaminergic strategy.

The FDA has approved Juvmo, the first and only dopamine agonist for adults with Parkinson’s disease designed to selectively ...

The ​US Food and ‌Drug Administration has approved AbbVie's drug ​for Parkinson's disease ​in adults, the health ⁠regulator's ...

Tavapadon (Juvmo) is a new once-daily pill for Parkinson’s motor symptoms. Here’s how it works, who it may help and what to ...

ALPHA | Overview of Technology◾️What is SciTech at Amneal Pharmaceuticals?Formulation technology that 'redesigns' complex ...

Since March 2026, drugmakers have been required to add a new warning to carbidopa/levodopa, the standard combination therapy ...

It’s true. Rates of Parkinson’s disease are growing faster than any other neurological condition in the world, with incidence projected to double in the coming decades. Parkinson’s is a progressive ...

AmMax Bio, Inc. ("AmMax”), a private clinical-stage biopharmaceutical company developing first- and best-in-class antibody drug conjugates (ADCs) for cancer patients, today announced the appointment ...